Coya Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with an emphasis on conditions such as ALS and Alzheimer's disease
The company leverages proprietary technology platforms to create treatments aimed at modulating the immune system and protecting neuronal health. By harnessing the potential of its unique approaches, Coya aims to improve the quality of life for patients suffering from debilitating neurological disorders while advancing the field of neurotherapeutics. Through rigorous research and development, the company strives to bring new hope to patients and their families by addressing unmet medical needs in the neurodegenerative space.
Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen.
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Coya Therapeutics Inc (NASDAQCOYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this type of manipulation has been associated with cancer treatments, innovative companies are applying the same principles to a wide variety of diseases.
Raymond James cut the price target for Brinker International, Inc. (NYSEEAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close at $36.39 on Tuesday.
